Contrast agent manufacturer Guerbet has received approval from the U.S. Food and Drug Administration (FDA) for a new indication for its Lipiodol contrast agent.
Lipiodol has been approved for selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC), the most common primary liver tumor and the third-leading cause of cancer-related death worldwide, according to Guerbet.
The announcement comes soon after the FDA granted approval to manufacture Lipiodol for U.S. distribution at a Jubilant HollisterStier site in Canada, the company said.
Lipiodol is now indicated for hysterosalpingography in adults, lymphography in adults and children, and selective hepatic intra-arterial use for imaging tumors in adults with known HCC.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
